Custom synthesis and SAR study of Narciclasine and Strophanthindin analogs. and high-throughput screening hit (Life Chemical E10)

The Center for Innovative Drug Discovery (CIDD) will provide Dr. Min Kang at Texas Tech Health Science Center with medicinal chemistry support to perform custom synthesis and SAR study of narciclasine and strophanthindin analogs. as well as the derivatives of high-throughput screening hit Life Chemical E10 chemotype. The CIDD will provide all the necessary services. qualified personnel. materials. equipment and the facilities to ensure the requested tasks are completed. The requested tasks may include the following activities: developing synthesis methods. optimizing reaction conditions. and justifying the acquirable target compounds. The CIDD will aim to deliver 5-20 mg supplies of the proposed target compounds that are outlined in the scheme below.